Les médicaments pour la perte de poids, une solution miracle ?

Obesity is a prevalent health problem affecting 29% of the Canadian population and having many complications (high blood pressure, dyslipidemia, diabetes, etc.). There are currently four treatments approved by Health Canada for weight loss: orlistat, the naltrexone/bupropion combination, liraglutide, and semaglutide at a dose of 2.4 mg (which is not yet sold in Canada). In this article, a review of the efficacy and safety data will be performed. Naltrexone/bupropion 32 mg/360 mg per day demonstrated a 5% weight reduction in 48% of patients (p < 0.000) in the COR-I study. Orslistat 120 mg PO TID had a mean weight loss of 10.2%, compared to 6.1% with placebo (p < 0.001). Semaglutide 2.4 mg subcutaneously weekly demonstrated a mean weight change of -14.9% in the semaglutide group and -2.4% in the placebo group (p < 0.001) in STEP-1. Liraglutide 3 mg subcutaneously once daily demonstrated -8% weight loss versus -2.6% with placebo (p < 0.001) in SCALE Obesity. Finally, tirzepatide demonstrated ≥ 5% weight loss in 89% to 91% of participants receiving 10 mg or 15 mg doses in SURMOUNT-1. [ABSTRACT FROM AUTHOR]